PMID- 33215332
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210619
IS  - 2509-4254 (Electronic)
IS  - 2509-4262 (Print)
IS  - 2509-4262 (Linking)
VI  - 5
IP  - 2
DP  - 2021 Jun
TI  - Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France.
PG  - 211-219
LID - 10.1007/s41669-020-00237-4 [doi]
AB  - OBJECTIVE: Our objectives were to describe the basal insulin treatment regimens 
      most widely used in a real-world setting in France and to estimate the associated 
      treatment costs in people with type 2 diabetes mellitus (T2DM). METHODS: A 
      cross-sectional observational study was conducted (November 2017-February 2018) 
      among adult patients with T2DM requiring basal insulin therapy for their own use 
      in a representative sample of pharmacies. Costs were compared between patients 
      treated with three recently marketed insulins (glargine 300 U/ml [Gla-300], 
      biosimilar glargine 100 U/ml [Gla-100] and a fixed-ratio combination of insulin 
      degludec and liraglutide) and those treated with three established basal or 
      intermediate insulins: branded glargine 100 U/ml, insulin detemir and neutral 
      protamine Hagedorn insulin [NPH]). RESULTS: Overall, 1933 patients were analysed. 
      Gla-300 accounted for 59.9% of novel basal insulin prescriptions, and branded 
      Gla-100 accounted for 67.9% of established insulin prescriptions. Recent insulins 
      were more frequently associated with glucagon-like peptide-1 (GLP-1) analogues. 
      Results confirmed a lower rate of severe hypoglycaemia with Gla-300 than with 
      Gla-100. On average, weekly total costs of treatment with all basal insulins were 
      not significantly different, except with detemir, where they were higher. 
      CONCLUSION: New basal insulins are expected to be integrated into clinical 
      practice. This analysis shows that their use does not impact upon the management 
      cost of insulin therapy in people with T2DM.
FAU - Detournay, Bruno
AU  - Detournay B
AUID- ORCID: 0000-0001-7843-4608
AD  - CEMKA-EVAL, 43, boulevard Marechal Joffre, 92340, Bourg-la-Reine, France. 
      bruno.detournay@cemka.fr.
FAU - Boultif, Zahra
AU  - Boultif Z
AD  - Sanofi, 94250, Gentilly, France.
FAU - Bahloul, Amar
AU  - Bahloul A
AD  - Sanofi, 94250, Gentilly, France.
FAU - Jeanbat, Viviane
AU  - Jeanbat V
AD  - CEMKA-EVAL, 43, boulevard Marechal Joffre, 92340, Bourg-la-Reine, France.
FAU - Robert, Julien
AU  - Robert J
AD  - CEMKA-EVAL, 43, boulevard Marechal Joffre, 92340, Bourg-la-Reine, France.
LA  - eng
PT  - Journal Article
DEP - 20201120
PL  - Switzerland
TA  - Pharmacoecon Open
JT  - PharmacoEconomics - open
JID - 101700780
PMC - PMC8160062
COIS- VJ, JR and BD are employed by CEMKA, a research and consulting firm providing 
      studies and advisory services for private and public organizations. BD has served 
      as an advisor, consultant or member of a speaker bureau for Merck Sharpe & Dohme 
      Corp., Novo Nordisk, Pfizer Inc. and Sanofi-Aventis. ZB and AB are employees of 
      Sanofi France.
EDAT- 2020/11/21 06:00
MHDA- 2020/11/21 06:01
PMCR- 2020/11/20
CRDT- 2020/11/20 05:52
PHST- 2020/10/21 00:00 [accepted]
PHST- 2020/11/21 06:00 [pubmed]
PHST- 2020/11/21 06:01 [medline]
PHST- 2020/11/20 05:52 [entrez]
PHST- 2020/11/20 00:00 [pmc-release]
AID - 10.1007/s41669-020-00237-4 [pii]
AID - 237 [pii]
AID - 10.1007/s41669-020-00237-4 [doi]
PST - ppublish
SO  - Pharmacoecon Open. 2021 Jun;5(2):211-219. doi: 10.1007/s41669-020-00237-4. Epub 
      2020 Nov 20.